Exviera dasabuvir: Phase IIIb data

The open-label, international Phase IIIb MALACHITE-II trial in 148 treatment-experienced patients with chronic HCV genotype 1 infection without cirrhosis showed that Viekirax ombitasvir/paritaprevir/ritonavir and Exviera with ribavirin for 12 weeks led to an SVR4 and SVR12 rate of 99% vs. an SVR4 rate of 68.1% for Incivek telaprevir plus peginterferon and ribavirin for 12 weeks followed by peginterferon and ribavirin alone for 12-36 weeks (p<=0.05 for SVR4 comparison). Data, including SVR12 data for the Incivek arm, will be presented at the European Association for the Study of the Liver meeting in Vienna this month. ...